Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2, 3, 4 months schedule with a fourth dose at 12-18 months of age

Human Vaccines

Volumn 6, Issue 8, 2010, Pages 640-651

  Habermehl, Pirmin ^a   Leroux Roels, Geert ^b   Sänger, Roland ^c   Mächler, Gudrun ^c   Boutriau, Dominique ^c,d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c GLAXOSMITHKLINE   (Germany)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Conjugate vaccine; Haemophilus influenzae type b; Meningitis; Neisseria meningitidis serogroup C; Neisseria meningitidis serogroup Y

Indexed keywords

ALUMINUM HYDROXIDE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA TETANUS PERTUSSIS HEPATITIS B POLIOMYELITIS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B NEISSERIA MENINGITIDIS TETANUS TOXOID CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; INFANTRIX; MENINGOCOCCUS VACCINE; MENITORIX; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANOREXIA; ANTIBODY RESPONSE; ARTICLE; BACTERIAL MENINGITIS; BACTERICIDAL ACTIVITY; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DROWSINESS; DRUG DOSAGE FORM COMPARISON; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEISSERIA MENINGITIDIS; PATIENT COMPLIANCE; PERTUSSIS; PHASE 2 CLINICAL TRIAL; POLIOMYELITIS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SEROTYPE; SIDE EFFECT; TETANUS; TREATMENT OUTCOME;

EID: 77956644610     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.8.12154     Document Type: Article

References (54)

1. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000; 13:302-17.
2. Miller E, Salisbury D, Ramsay M. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20:58-67.
3. Goldblatt D. Recent developments in bacterial conjugate vaccines. J Med Microbiol 1998; 47:563-7. (Pubitemid 28313943)
4. Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003; 326:365-6. (Pubitemid 36241472)
5. Hviid A, Melbye M. Impact of routine vaccination with a conjugate Haemophilus influenzae type b vaccine. Vaccine 2004; 22:378-82.
6. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7. (Pubitemid 38970013)
7. Kelly DF, Moxon R, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology 2004; 113:163-74.
8. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003; 188:481-5.
9. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88.
10. Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999; 93:341-53.
11. Australian Meningoccocal Surveillance Program. Annual report of the Australian Meningococcal Surveillance Programme, 2006. Commun Dis Intell 2006; 30:211-21.
12. Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, Brehony C, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31:27-36. (Pubitemid 46058817)
13. Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, et al. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J Infect Dis 1999; 180:1894-901.
14. Agudelo CI, Sanabria OM, Ovalle MV. Serogroup Y meningococcal disease, Colombia. Emerg Infect Dis 2008; 14:990-1.
15. Pollard AJ, Scheifele D. Meningococcal disease and vaccination in North America. J Paediatr Child Health 2001; 37:20-7.
16. Center for Disease Control and Prevention. Active Bacterial Core Surveillance Report, emerging Infections Program Network, Neisseria meningitidis. Available via the Internet: http://www.cdc.gov/abcs/survreports. htm (Accessed 2009).
17. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27:51-63.
18. Snape MD, Pollard AJ. Meningococcal polysaccharide-protein conjugate vaccines. Lancet Infect Dis 2005; 5:21-30.
19. Lingappa JR, Rosenstein N, Zell ER, Shutt KA, Schuchat A, Perkins BA. Active Bacterial Core surveillance (ABCs) team. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States. Vaccine 2001; 19:4566-75.
20. Rennels M, King J Jr, Ryall R, Papa T, Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004; 23:429-35. (Pubitemid 38621482)
21. MENVEO® Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine. Product Information. Novartis.
22. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27:161-8.
23. Pace D, Pollard AJ. Meningococcal A, C, Y and W-135 polysaccharide- protein conjugate vaccines. Arch Dis Child 2007; 92:909-15.
24. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist C. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria- tetanuspertussis containing acellular pertussis. Lancet 1999; 354:2063-8.
25. Tichmann I, Preidel H, Grunert D, Habash S, Schult R, Maier R, et al. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 2005; 23:3272-9.
26. Tichmann I, Grunert D, Habash S, Preidel H, Schult R, Pfletschinger U, et al. Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccines and evaluation of booster vaccination. Human Vaccines 2006; 2:249-54.
27. Schmitt HJ, von Kries R, Hassenpflug B, Hermann M, Siedler A, Niessing W, et al. Haemophilus influenzae type b disease: impact and effectiveness of diphtheria- tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H.influenzae type b combination vaccines. Pediat Infect Dis J 2001; 20:767-74.
28. Kalies H, Verstraeten T, Grote V, Meyer N, Siedler A, Schmitt HJ, et al. Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b and diphtheria- tetanus toxoids-acellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Germany. Pediatr Infect Dis J 2004; 23:944-50.
29. Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez- Campderá JA, Navarro ML, et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 2006; 25:713-20.
30. Kitchin NR, Southern J, Morris R, Hemme F, Thomas S, Watson MW, et al. Evaluation of a diphtheriatetanus- acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age. Arch Dis Child 2007; 92:11-6.
31. Schmitt HJ, Maechler G, Habermehl P, Knuf M, Saenger R, Begg N, et al. Immunogenicity, reactogenicity and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin Vaccine Immun 2007; 14:426-34.
32. Tejedor JC, Moro M, Ruiz-Contreras J, Castro J, Gómez- Campderá JA, Navarro ML, et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 2006; 25:713-20.
33. Southern J, Borrow R, Andrews N, Morris R, Waight P, Hudson M, et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clin Vaccine Immunol 2009; 16:194-9.
34. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody activity. Vaccine 2005; 23:2222-7. (Pubitemid 40341456)
35. Auckland C, Gray S, Borrow R, Andrews N, Goldblatt D, Ramsay M, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006; 194:1745-52. (Pubitemid 44902007)
36. Richmond P, Borrow R, Findlow J, Martin S, Thornton C, Cartwright K, et al. Evaluation of De-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming and bactericidal activity against O-acetylated and De-O-acetylated serogroup C strains. Infect Immun 2001; 69:2378-82. (Pubitemid 32239706)
37. Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183:160-3. (Pubitemid 32043057)
38. th Annual meeting of the Infectious Disease Society of America (IDSA), 4-7 October 2007, San Diego CA, USA.
39. Kafetzis DA, Stamboulidis KN, Tzanakaki G, Kourea Kremastinou J, Skevaki CL, Konstantopoulos A, et al. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians. Clin Microbiol Infect 2007; 13:550-2.
40. Borrow R, Andrews N, Findlow H, Waight P, Southern J, Crowley-Luke A, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010; 17:154-9.
41. Balmer P, Borrow R. Serologic correlates of protection for evaluation the response to meningococcal vaccines. Expert Rev Vaccines 2004; 3:77-86.
42. Donaldson L, Beasley C, Ridge K. Department of Health. Important changes to the childhood immunisation programme. Available at http://www. immunisation.nhs.uk/files/CMOCNOCPHOletterchangestoscheduleJuly2006.pdf (accessed 2007).
43. Tichmann-Schumann I, Soemantri P, Behre U, Disselhoff J, Mahler H, Maechler G, et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis b-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2005; 24:70-7.
44. Saenger R, Maechler G, Potreck M, Zepp F, Knuf M, Habermehl P, et al. Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered separately. Vaccine 2005; 23:1135-43. (Pubitemid 40063547)
45. Nolan T, Roberton D, Marshall H, Marshall H, Richmond P, Streeton C, et al. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and pneumococcal vaccine in infants. Vaccine 2007; 25:8487-99.
46. Marchant CD, Miller JM, Marshall GS, Blattter M, Aris E, Friedland LR, et al. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Accepted for publication.
47. Zepp F, Schuind A, Meyer C, Sänger R, Kaufhold A, Willems P. Safety and reactogenicity of a novel DTPa-HBV-IPV combined vaccine given along with commercial Hib vaccines in comparison with separate concomitant administration of DTPa, Hib, and OPV vaccines in infants. Pediatrics 2002; 109:158.
48. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 1997; 4:156-67.
49. Gheesling LL, Carlone GM, Pais LB, Holder PF, Maslanka SE, Plikaytis BD, et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized Enzyme-Linked Immunosorbent Assay. J Clin Microbiol 1994; 32:1475-82.
50. Goldblatt D, Vaz AR, Miller E. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J Infect Dis 1998; 177:1112-5.
51. Richmond P, Goldblatt D, Fusco PC, Fusco JD, Heron I, Clark S, et al. Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 2000; 18:641-6.
52. Käyhty H, Peltola, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983; 147:1100.
53. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1984; 149:1034-5.
54. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from post licensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780-6. (Pubitemid 37129487)